Labcorp Holdings Inc. (LH) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Labcorp’s revenue went from $9.6B in fiscal 2016 to $14.0B in fiscal 2025, growth of about 4.3% a year.
Net income in fiscal 2025 was $876M, a net margin of 6.3%; the best year in this period was 2021 with $2.4B.
Over the twelve months to September 30, 2026, revenue was $14.6B and net income $1.0B.
Free cash flow was $1.2B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 20% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6B | $14.0B | $13.0B | $12.2B | $11.9B | $13.1B | $14.0B | $11.6B | $11.3B | $10.3B | $9.6B |
| Gross profit | $4.2B | $4.0B | $3.6B | $3.4B | $3.7B | $5.0B | $5.0B | $3.3B | $3.2B | $3.1B | $2.9B |
| Operating income | $1.5B | $1.4B | $1.1B | $726M | $1.4B | $3.0B | $2.4B | $1.3B | $1.3B | $1.3B | $1.3B |
| Net income | $1.0B | $876M | $746M | $418M | $1.3B | $2.4B | $1.6B | $824M | $884M | $1.2B | $712M |
| EPS (diluted) | $12.19 | $10.46 | $8.84 | $4.77 | $13.97 | $24.39 | $15.88 | $8.35 | $8.61 | $11.81 | $6.82 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +7.2% | +7.0% | +2.5% | −9.7% | −6.0% | +21.0% | +1.9% | +10.0% | +7.9% | +10.1% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.8B | $1.6B | $1.6B | $1.3B | $2.0B | $3.1B | $2.1B | $1.4B | $1.3B | $1.5B | $1.2B |
| Capital spending | -$528M | -$434M | -$490M | -$454M | -$429M | -$422M | -$382M | -$400M | -$380M | -$313M | -$279M |
| Free cash flow | $1.3B | $1.2B | $1.1B | $874M | $1.5B | $2.7B | $1.8B | $1.0B | $926M | $1.2B | $918M |
| Dividends paid | $237M | $241M | $243M | $254M | $195M | $0 | $0 | — | — | — | — |
| Buybacks | $677M | $450M | $250M | $1.0B | $1.1B | $1.7B | $100M | $450M | $700M | $338M | $44M |
| Stock-based pay | $127M | $126M | $117M | $129M | $117M | $133M | $112M | $107M | $92M | $110M | $110M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $532M | $1.5B | $537M | $321M | $1.5B | $1.3B | $338M | $427M | $317M | $434M |
| Debt | — | $6.5B | $7.2B | $5.9B | $6.2B | $6.2B | $6.7B | $7.0B | $6.0B | $6.8B | $5.8B |
| Equity | — | $8.6B | $8.1B | $7.9B | $10.1B | $10.3B | $9.4B | $7.6B | $7.0B | $6.8B | $5.5B |
| Total assets | — | $18.4B | $18.4B | $16.7B | $20.2B | $20.4B | $20.1B | $18.0B | $16.2B | $16.7B | $14.2B |
| Shares (diluted) | 82M | 84M | 84M | 88M | 92M | 98M | 98M | 99M | 103M | 104M | 104M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 29.0% | 28.8% | 27.9% | 27.7% | 31.3% | 38.0% | 35.4% | 28.1% | 28.0% | 30.0% | 29.9% |
| Operating margin | 10.3% | 9.9% | 8.3% | 6.0% | 12.1% | 23.2% | 17.5% | 11.5% | 11.7% | 12.7% | 13.3% |
| Net margin | 6.9% | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% | 11.1% | 7.1% | 7.8% | 11.9% | 7.4% |
| FCF margin | 8.8% | 8.6% | 8.4% | 7.2% | 12.9% | 20.5% | 12.5% | 9.0% | 8.2% | 11.5% | 9.6% |
| ROIC | — | 7.2% | 5.6% | 4.2% | 7.0% | 14.6% | 12.0% | 7.2% | 8.0% | 7.6% | 8.8% |
| ROE | — | 10.2% | 9.3% | 5.3% | 12.7% | 23.1% | 16.5% | 10.8% | 12.5% | 18.0% | 12.9% |
Frequently asked questions
What is Labcorp’s annual revenue?
$14.0B in fiscal 2025 and $14.6B over the twelve months to September 30, 2026.
How much profit does Labcorp make?
Net income was $876M in fiscal 2025 (net margin 6.3%).
Is Labcorp’s revenue growing?
Yes: revenue rose 7.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.